Neuropathix, Inc. (NPTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Neuropathix, Inc. (NPTX) trades at $0.00. Neuropathix, Inc. is a biopharmaceutical company focused on developing novel therapeutics derived from synthetic cannabinoid derivatives. Market cap: $28,143, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for NPTX: NPTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NPTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NPTX: 1/1 perspectives are bearish.
Neuropathix, Inc. (NPTX) Healthcare & Pipeline Overview
Neuropathix, Inc. is a biopharmaceutical firm specializing in synthetic cannabinoid-based therapeutics for neurological disorders. With a focus on pre-clinical drug development, they aim to address unmet needs in areas like chemotherapy-induced peripheral neuropathy and traumatic brain injury, operating in the competitive biotechnology sector.
What Is the Investment Thesis for NPTX?
Neuropathix, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on synthetic cannabinoid therapeutics for neurological disorders addresses a significant market need. Key value drivers include the successful progression of its drug candidates, such as KLS-13019, through pre-clinical development and into clinical trials. Positive pre-clinical data and subsequent clinical trial results could serve as major catalysts, driving investor interest and potentially leading to partnerships or acquisitions. However, the company's limited financial resources, reflected in its $0 market capitalization and negative profit margin of -2176.0%, pose a significant risk. Successful navigation of the regulatory landscape and securing additional funding will be critical for Neuropathix to realize its potential.
Based on FMP financials and quantitative analysis
NPTX Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.01 reflects the company's current lack of profitability and reliance on future drug development success.
- Profit margin of -2176.0% highlights the substantial expenses associated with research and development in the biopharmaceutical industry.
- Gross margin of 100.0% suggests that once products are commercialized, the company has the potential for high profitability, but this is contingent on successful drug development.
- Beta of 1.65 indicates that the stock is more volatile than the market, reflecting the speculative nature of biotechnology investments.
Who Are NPTX's Competitors?
NPTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | 3B | 68 |
| CELU Celularity Inc. | $0.73 | +0.44% | $17.56M | 68 |
| PRVB Provention Bio, Inc. | $24.98 | +0.00% | $2.38B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NPTX's Key Strengths?
- Proprietary synthetic cannabinoid platform.
- Focus on neurological disorders with unmet needs.
- Early-stage development of novel therapies.
- Experienced management team.
What Are NPTX's Weaknesses?
- Limited financial resources.
- Early-stage development with high risk of failure.
- Dependence on successful clinical trials and regulatory approvals.
- Small number of employees.
What Could Drive NPTX Stock Higher?
- Publication of pre-clinical data for KLS-13019 in a peer-reviewed journal (estimated within 6-12 months).
- Initiation of Phase 1 clinical trials for KLS-13019 (estimated within 12-18 months).
- Continued research and development of new synthetic cannabinoid derivatives.
- Pursuit of strategic partnerships and licensing agreements with larger pharmaceutical companies.
What Are the Key Risks for NPTX?
- Failure of clinical trials for drug candidates.
- Inability to secure additional funding to support research and development.
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory hurdles and delays in obtaining drug approvals.
- Limited financial resources and high cash burn rate.
What Are the Growth Opportunities for NPTX?
- Advancement of KLS-13019: KLS-13019, a lead drug candidate, targets chemotherapy-induced peripheral neuropathy (CIPN). The market for CIPN treatments is expanding, driven by the increasing use of chemotherapy in cancer treatment. Successful completion of pre-clinical studies and initiation of Phase 1 clinical trials could significantly increase the company's valuation. The timeline for reaching Phase 1 is estimated at 12-18 months, with potential market entry in 5-7 years, pending regulatory approvals.
- Development of KLS-13023 for Hepatic Encephalopathy: KLS-13023 is being developed for the treatment of overt hepatic encephalopathy, a neurological complication of liver disease. The market for hepatic encephalopathy treatments is growing due to the rising prevalence of liver diseases. Neuropathix aims to demonstrate the efficacy of KLS-13023 in pre-clinical models and advance it to clinical trials. The timeline for reaching Phase 1 is estimated at 18-24 months, with potential market entry in 6-8 years, pending regulatory approvals.
- Expansion into Mild Traumatic Brain Injury (mTBI) Treatments: Neuropathix is exploring the use of its synthetic cannabinoids for the treatment of mild traumatic brain injury. The mTBI market is substantial, driven by sports-related injuries and accidents. The company's research focuses on developing therapies to reduce inflammation and promote neuronal recovery. Pre-clinical studies are ongoing, with potential for clinical trials in 2-3 years. Market entry is projected in 7-9 years, contingent on successful trials and regulatory approvals.
- Partnerships and Licensing Agreements: Neuropathix can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships can provide funding, expertise, and access to larger markets. The company is actively seeking potential partners to advance its pipeline. A successful partnership could provide a significant boost to the company's resources and valuation within the next 12-24 months.
- Expansion of the Cannabinoid Derivatives Platform: Neuropathix can expand its proprietary synthetic cannabinoid derivatives platform to discover and develop new therapies for other neurological disorders. This platform expansion can create a pipeline of drug candidates and increase the company's long-term growth potential. The company is continuously researching and developing new cannabinoid derivatives. New drug candidates could enter pre-clinical development within the next 2-3 years.
What Opportunities Does NPTX Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of the cannabinoid derivatives platform.
- Positive clinical trial results leading to increased valuation.
- Growing market for neurological disorder treatments.
What Threats Does NPTX Face?
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and delays.
- Failure of clinical trials.
- Inability to secure additional funding.
What Are NPTX's Competitive Advantages?
- Proprietary synthetic cannabinoid derivatives platform.
- Focus on specific neurological indications with unmet medical needs.
- Early-stage development of novel therapies with potential for patent protection.
What Does NPTX Do?
Neuropathix, Inc., founded in 2010 and based in Doylestown, Pennsylvania, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. The company's core focus lies in its proprietary synthetic cannabinoid derivatives platform, from which it develops treatments for a range of neurological conditions. Neuropathix, formerly known as Kannalife, Inc. until its name change in November 2020, is involved in the research and development of chemical entities such as KLS-13019, KLS-13023, and KLS-13022, along with related molecules. These compounds are being explored as potential treatments for chemotherapy-induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. Neuropathix operates through pre-clinical drug discovery and development processes, aiming to bring innovative synthetic cannabidiol therapeutics to market. The company's strategy centers on addressing significant unmet medical needs in neurological disorders through its unique cannabinoid platform.
What Products and Services Does NPTX Offer?
- Develops novel therapeutics from synthetic cannabinoid derivatives.
- Conducts research and development of chemical entities like KLS-13019, KLS-13023, and KLS-13022.
- Focuses on pre-clinical drug discovery and development.
- Targets disease indications such as chemotherapy-induced peripheral neuropathy.
- Aims to treat overt hepatic encephalopathy.
- Explores treatments for mild and chronic traumatic brain injuries.
How Does NPTX Make Money?
- Develops proprietary synthetic cannabinoid derivatives.
- Out-licenses or partners with larger pharmaceutical companies for clinical trials and commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties on future sales of approved drugs.
What Industry Does NPTX Operate In?
Neuropathix, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant financial risk. The market for neurological disorder treatments is substantial and growing, driven by an aging population and increasing awareness of conditions like traumatic brain injury and neuropathy. Competition is fierce, with both large pharmaceutical companies and smaller biotechs vying for market share. Neuropathix aims to differentiate itself through its proprietary synthetic cannabinoid platform, targeting specific neurological indications with potentially novel therapies. Success in this industry requires strong scientific expertise, effective clinical trial execution, and strategic partnerships.
Who Are NPTX's Key Customers?
- Pharmaceutical companies seeking novel therapeutics for neurological disorders.
- Patients suffering from chemotherapy-induced peripheral neuropathy.
- Individuals with overt hepatic encephalopathy.
- Patients with mild or chronic traumatic brain injury.
NPTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Neuropathix's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions around the company's innovative approach to pain management gaining traction.
- The company's recent partnerships have created buzz, signaling a possible expansion in its market reach and product offerings.
- Market perception is improving as Neuropathix is being recognized for its unique value proposition in a competitive healthcare landscape.
Bear Case
- Concerns remain about the company's ability to scale its operations effectively, which could hinder long-term growth prospects.
- Recent social media sentiment reflects skepticism regarding the sustainability of its current innovations and market positioning.
- Insider selling activity in the past raised questions about confidence levels among some stakeholders, impacting overall sentiment.
- The competitive landscape in the biotech sector is intensifying, with emerging players potentially overshadowing Neuropathix's advancements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NPTX Latest News
No recent news available for NPTX.
NPTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NPTX.
Price Targets
Wall Street price target analysis for NPTX.
NPTX MoonshotScore
What does this score mean?
The MoonshotScore rates NPTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Dean Petkanas
CEO
Dean Petkanas serves as the CEO of Neuropathix, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on strategic development and corporate leadership. He has held various executive positions in both public and private companies, contributing to the advancement of innovative therapies. Petkanas brings a wealth of knowledge in drug development, regulatory affairs, and commercialization strategies to Neuropathix.
Track Record: Under Dean Petkanas's leadership, Neuropathix has focused on advancing its pre-clinical pipeline of synthetic cannabinoid therapeutics. Key milestones include the development of KLS-13019, KLS-13023, and KLS-13022 for various neurological disorders. Petkanas has overseen the company's efforts to secure funding and establish strategic partnerships to support its research and development programs.
NPTX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Neuropathix, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies on this tier often have limited trading volume and may not provide regular financial reporting. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, leading to increased risk for investors due to the potential for less transparency and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- OTC Other tier companies may be subject to less regulatory oversight, increasing the risk of fraud or mismanagement.
- Potential for delisting or suspension from the OTC market due to non-compliance with regulations.
- Higher volatility compared to stocks listed on major exchanges.
- Verify the company's financial statements and SEC filings, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues involving the company.
- Monitor trading volume and bid-ask spreads to assess liquidity.
- Consult with a financial advisor before investing.
- Focus on developing therapeutics for neurological disorders.
- Management team with experience in the pharmaceutical and biotechnology industries.
- Proprietary synthetic cannabinoid derivatives platform.
- Pre-clinical development of drug candidates targeting specific disease indications.
NPTX Healthcare Stock FAQ
What does Neuropathix, Inc. do?
Neuropathix, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics derived from its proprietary synthetic cannabinoid derivatives platform. The company is engaged in pre-clinical drug discovery and development processes, targeting disease indications such as chemotherapy-induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. Neuropathix aims to address unmet medical needs in neurological disorders through its unique cannabinoid platform.
What do analysts say about NPTX stock?
As of March 18, 2026, there is no available analyst coverage or consensus rating for NPTX stock. The company's micro-cap status and listing on the OTC Other tier may limit analyst interest. Key valuation metrics, such as price-to-earnings and price-to-sales ratios, are not meaningful due to the company's current lack of profitability. Growth considerations revolve around the successful advancement of its drug candidates through pre-clinical and clinical development.
What are the main risks for NPTX?
The main risks for Neuropathix, Inc. include the inherent uncertainties of drug development, the need for significant capital to fund research and clinical trials, and the competitive landscape of the biotechnology industry. The company's reliance on its synthetic cannabinoid derivatives platform also poses a risk, as the efficacy and safety of these compounds must be demonstrated in clinical trials. Additionally, the company's listing on the OTC Other tier carries increased risks related to liquidity, transparency, and regulatory oversight.
What are the key factors to evaluate for NPTX?
Evaluate NPTX on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does NPTX data refresh on this page?
NPTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NPTX's recent stock price performance?
Neuropathix, Inc. (NPTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary synthetic cannabinoid platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NPTX overvalued or undervalued right now?
Valuing Neuropathix, Inc. (NPTX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NPTX?
Before investing in Neuropathix, Inc. (NPTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company's financial condition and future prospects are highly speculative.
- Investment in NPTX carries significant risk.